COMMUNIQUÉS West-GlobeNewswire

Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
27/05/2026
Company also advances fibrin/VEGF bispecific antibody THN622, a potential new standard of care for retinal neurodegeneration SACRAMENTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage [...]
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
27/05/2026
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company [...]
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
27/05/2026
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability [...]
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
Invivyd to Participate in Upcoming Investor Events
27/05/2026
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New York [...]
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
27/05/2026
MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will [...]
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026
Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cells SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a [...]
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated study in [...]
Transforming Rural Health Care Through a First-of-its-Kind Collaborative
27/05/2026
A study designed to address rural pharmacy deserts by bringing pharmacy services directly into the home BLOOMINGTON, Minn., May 27, 2026 (GLOBE NEWSWIRE) -- Ōmcare and PharMerica are proud to announce the launch of the [...]
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026
ALLENTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection [...]
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for [...]
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
27/05/2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
27/05/2026
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s [...]
Medline announces participation in upcoming investor conferences
27/05/2026
NORTHFIELD, Ill., May 27, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that members of the executive leadership team will be participating in the following investor conferences. Mike [...]
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
27/05/2026
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in [...]
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
27/05/2026
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
27/05/2026
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, [...]

Pages